* Vir Biotechnology Inc VIR.OQ reported a quarterly
adjusted
loss of $1.02 per share for the quarter ended in June, higher
than the same quarter last year, when the company reported EPS
of $-1.45. The mean expectation of eight analysts for the
quarter was for a loss of 90 cents per share. Wall Street
expected results to range from $-1.10 to -54 cents per share.
* Revenue fell 19% to $3.08 million from a year ago;
analysts
expected $7.50 million.
* Vir Biotechnology Inc's reported EPS for the quarter was a
loss
of $1.02.
* The company reported a quarterly loss of $138.38 million.
* Vir Biotechnology Inc shares had risen by 14.2% this
quarter and
gained 1.0% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by
about 3.9%
in the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"
Wall Street's median 12-month price target for Vir Biotechnology
Inc is $20.00
This summary was machine generated from LSEG data August 1 at
09:37 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Jun. 30 2024 -0.90 -1.02 Missed
Mar. 31 2024 -1.05 -0.48 Beat
Dec. 31 2023 -1.01 -0.86 Beat
Sep. 30 2023 -1.21 -1.22 Missed